What are the FDA‑approved indications, dosing recommendations, and contraindications for using sugammadex in pediatric patients aged 2 years and older?

Sugammadex Use in Pediatric Patients According to FDA

The FDA has NOT approved sugammadex for pediatric patients under 18 years of age. According to the official FDA prescribing information, "Safety and effectiveness of BRIDION have not been established in patients ≤ 17 years of age" 1.

Critical FDA Position

The FDA drug label explicitly states that sugammadex is contraindicated in pediatric populations, despite its approval for adult use since 2015 1. This represents a significant divergence between FDA approval status and clinical practice patterns, as emerging evidence suggests widespread off-label use in children.

Off-Label Clinical Context

While the FDA has not approved pediatric use, recent research demonstrates that sugammadex is being used extensively in pediatric anesthesia practice in the United States. A 2025 retrospective study of 97,654 pediatric cases found that 47.1% received sugammadex for neuromuscular blockade reversal 2. This widespread off-label use occurs despite the absence of FDA approval.

Dosing Patterns in Off-Label Pediatric Use

When used off-label in children, the dosing mirrors adult recommendations based on depth of neuromuscular blockade 3:

• Moderate blockade (2-4 TOF responses): 2 mg/kg achieves TOF ratio ≥0.9 in approximately 1.6 minutes 4
• Deep blockade (1-2 post-tetanic counts): 4 mg/kg achieves reversal in approximately 2.0 minutes 4
• Immediate reversal after rocuronium: 16 mg/kg (adult dose) within 3 minutes of rocuronium 1.2 mg/kg 1

Evidence Supporting Pediatric Use (Despite FDA Non-Approval)

A 2022 phase IV randomized trial in 288 children aged 2 to <17 years demonstrated that sugammadex 2 mg/kg reversed moderate neuromuscular blockade significantly faster than neostigmine (1.6 minutes vs 7.5 minutes, p<0.0001) 4. The study found no meaningful differences in clinically relevant bradycardia (2.0% vs 5.9%), hypersensitivity, or anaphylaxis compared to neostigmine 4.

A 2016 meta-analysis of 253 pediatric patients (ages 2-18 years) confirmed faster reversal times with sugammadex versus neostigmine, with weighted mean differences of -7.15 minutes for 2 mg/kg and -17.32 minutes for 4 mg/kg 5.

Critical Safety Concerns in Pediatric Populations

Bone and Dental Toxicity

The most concerning finding from FDA review involves bone toxicity in juvenile animals. Juvenile rat studies demonstrated that sugammadex concentrations in bone were 13% of administered dose in young rats versus only 3% in adults 1. In 7-day-old rats receiving 120-500 mg/kg daily for 28 days, there was:

• 3% decrease in ulna and femur bone length (did not recover after 8 weeks)
• Whitish discoloration and enamel formation disturbance in incisors
• Molar effects at highest doses 1

These findings likely contributed to FDA's decision not to approve pediatric use, particularly in children under 2 years where bone development is most active.

Age-Specific Considerations

The 2025 retrospective study found that younger age groups were more likely to receive sugammadex when used off-label, with neonates (0-27 days) having 2.59 times higher odds and infants (28 days-1 year) having 2.72 times higher odds compared to adolescents 2. This pattern is concerning given the bone toxicity data in juvenile animals.

Clinical Decision Factors When Considering Off-Label Use

Factors associated with off-label sugammadex use in pediatric practice include 2:

• Higher medical complexity: ASA III (OR 1.32) and ASA IV (OR 1.71) patients
• Neuromuscular disease: OR 1.14
• Cardiac surgery: OR 1.76
• Higher neuromuscular blockade doses: >2 ED95s/kg within the hour before reversal (OR 4.58)
• Shorter case duration: <60 minutes (OR 2.06)

Monitoring Requirements

Quantitative neuromuscular monitoring is mandatory when using sugammadex, regardless of age 3. The dose must be determined by the depth of blockade at time of reversal, and monitoring must continue post-administration to detect potential recurarization 3.

Common Pitfalls

1. Using sugammadex in infants and neonates without considering bone toxicity risk - The juvenile animal data suggests highest risk in youngest patients
2. Failing to recognize FDA non-approval status - This is off-label use requiring informed consent discussion
3. Inadequate neuromuscular monitoring - Dosing cannot be determined without objective assessment of blockade depth
4. Assuming pediatric approval based on adult approval - The FDA explicitly excluded pediatric patients from approval

Contraception Considerations in Adolescents

For female adolescent patients of reproductive potential using hormonal contraceptives, sugammadex reduces contraceptive efficacy for 7 days post-administration. An additional non-hormonal contraceptive method must be used for the next 7 days 1.